We've all heard the promise: AI will transform biopharma strategy. But when we tested leading LLMs (Claude, Copilot, Gemini) on real in-licensing opportunities, they failed 64-77% of the time.
The problem? Off-the-shelf AI lacks three critical elements:
So we built Scitaris-AI differently.
Here we systematically integrated our proprietary intelligence databases, expert SOPs, and PhD-level analytical protocols. The result: up to 95% accuracy and 94% reproducibility in evaluating strategic dimensions like development status, transactability, and competitive differentiation.
Scitaris-AI works as a configurable companion system, enabling our teams to conduct broader, deeper analyses while maintaining the rigor high-stakes decisions demand.
Key takeaway: Reliable AI for pharma strategy requires more than better prompts. It requires systematic integration of domain expertise, curated data, and structured frameworks that mirror how experts actually think.
